Raphael Pharma Approves $5M Stock Buyback

TL;DR

Raphael Pharma is buying back up to $5M in stock, signaling confidence.

AI Summary

Raphael Pharmaceutical Inc. announced on August 11, 2025, that its Board of Directors approved a new stock repurchase program. The company is authorized to repurchase up to $5 million of its common stock over the next 12 months, commencing August 7, 2025. This move indicates management's confidence in the company's valuation and its commitment to returning value to shareholders.

Why It Matters

This stock repurchase program signals management's belief that the company's stock is undervalued, potentially boosting investor confidence and share price.

Risk Assessment

Risk Level: medium — Stock repurchase programs can be positive, but the actual impact depends on the company's financial health and the market conditions.

Key Numbers

• $5.0M — Stock Repurchase Program (Authorization for share buybacks over 12 months.)

Key Players & Entities

• Raphael Pharmaceutical Inc. (company) — Registrant
• $5 million (dollar_amount) — Stock repurchase authorization
• August 11, 2025 (date) — Report date
• August 7, 2025 (date) — Commencement of repurchase program

FAQ

Filing Documents

• ea0252574-8k_raphael.htm (8-K) — 28KB
• 0001213900-25-073909.txt ( ) — 185KB
• raph-20250807.xsd (EX-101.SCH) — 3KB
• raph-20250807_lab.xml (EX-101.LAB) — 33KB
• raph-20250807_pre.xml (EX-101.PRE) — 22KB
• ea0252574-8k_raphael_htm.xml (XML) — 3KB

01. Other Events

Item 8.01. Other Events On August 7, Raphael Pharmaceutical Inc. (the "Company" or "Raphael") completed its product development and is ready to launch its proprietary natural formula under the " RaphaWell" Brand for rheumatoid arthritis ("RA") support in the United States. This follows the successful completion of a proof-of-concept clinical trial (the "Study"), conducted under IRB approval and in full compliance with FDA regulations, including participants with severe RA, as previously disclosed on a Form 8-K on December 30, 2024. The Company intends to engage with a manufacturer in the United States to scale production. The finalized "RaphaWell" product, will be sold as a standalone clinically tested dietary supplement targeting the growing wellness market. The "RaphaWell" product is 100% natural, plant-based, and was associated with no reported side effects during the Study, addressing a significant unmet need in RA symptom management. Raphael's "RaphaWell" formula has undergone clinical testing, which we believe sets it apart in both credibility and efficacy from other products in the market. As previously disclosed in the Company's Current Report on Form 8-K, filed on December 30, 2024, the Study results showed an improvement in health-related parameters, as evaluated through questionnaires. For example, pain levels dropped from 75% participants reporting a negative result to 50% in week 8 and morning stiffness showed a notable reduction from 75% participants reporting such symptom at baseline to 41.67% at week 8. We believe that Raphael's "RaphaWell" formula holds strong commercial potential and first-mover advantage. Detailed study data will be available to consumers via QR code on the product packaging. Cautionary Note Concerning Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAPHAEL PHARMACEUTICAL INC. By: /s/ Shlomo Pilo Name: Shlomo Pilo Title: Chief Executive Officer Date: August 11, 2025 2

View Full Filing

View this 8-K filing on SEC EDGAR